Amphastar Pharmaceuticals, Inc. (AMPH) 10-Q Quarterly Report Thu Nov 09 2017

RANCHO CUCAMONGA, CA – November 8, 2017 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2017.

Third Quarter Highlights

Net revenues of $57.9 million for the third quarter

GAAP net income of $0.2 million, or $0.00 per diluted share, for the third quarter

Adjusted non-GAAP net income of $3.5 million, or $0.07 per diluted share, for the third quarter

Dr. Jack Zhang, Amphastar’s CEO, commented: “The third quarter was a successful one for Amphastar with approvals of both sodium bicarbonate and neostigmine. Approvals like these will help us diversify our sales base.”


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
	(in thousands, except per share data)
Net revenues	$	57,916	$	64,223	$	179,773	$	191,622
GAAP net income	$	175	$	3,890	$	3,040	$	13,274
Adjusted non-GAAP net income*	$	3,495	$	6,648	$	13,399	$	22,557
GAAP diluted EPS	$	0.00	$	0.08	$	0.06	$	0.29
Adjusted non-GAAP diluted EPS*	$	0.07	$	0.14	$	0.28	$	0.49

The following information was filed by Amphastar Pharmaceuticals, Inc. (AMPH) on Wednesday, November 8, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1297184/000129718417000035/amph-20170930x10q.htm

View differences made from one quarter to another to evaluate Amphastar Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Amphastar Pharmaceuticals, Inc..

Continue

Assess how Amphastar Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Amphastar Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Amphastar Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 10.1: Material Contract

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: AMPH
CIK: 1297184
Form Type: 10-Q Quarterly Report
Accession Number: 0001297184-17-000035
Submitted to the SEC: Wed Nov 08 2017 8:27:48 PM EST
Accepted by the SEC: Thu Nov 09 2017
Period: Saturday, September 30, 2017
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/amph/0001297184-17-000035.htm

Amphastar Pharmaceuticals, Inc. (AMPH) SEC Filing 10-Q Quarterly report for the period ending Saturday, September 30, 2017

SEC Filings

AMPH Valuations

AMPH Annual Reports

AMPH Quarterly Reports

AMPH Corporate News